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Introduction. Despite improvements in radiotherapy techniques, a substantial percentage of prostate cancer patients treated
with external beam radiotherapy still suffer from clinically relevant radio-induced toxicity. Variability in radiotherapy response
is mainly due to dosimetric factors, additional treatments and patient characteristics. However, nowadays there is increasing
evidence supporting the heritability of this phenotype. Most studies attempting to unravel the genetic background of radio-
induced toxicity, following a candidate gene approach, have been unable to replicate previous ﬁndings.
Objective. We aimed to identify new loci associated with the development of radio-induced toxicity through a genome-wide
association approach. Methods Samples were obtained from 735 unselected Galician (NW Spain) prostate cancer patients treated
at the RadiationOncologyDepartment of the Clinical UniversityHospital of Santiago deCompostela from2006 to 2011 (RADIOGEN
study). Morbidity was prospectively documented using the Common Terminology Criteria for Adverse Events v3.0. Standardised
total average toxicity (STAT) score was derived to assess acute and late overall toxicity. Univariate analyses were performed by
linear regression by comparison of allele frequencies, and covariates, with overall acute or late STAT scores. Multivariate analyses
of overall acute and late toxicity included those covariates with univariate p-values lower than 0.05. Multivariate linear regression
residuals were calculated for each patient to quantify the non-accounted toxicity by the available covariates.
Results. Nineteen covariateswere included into themultivariatemodel for acute toxicity, while the late toxicitymodelwas deﬁned
by three covariates, being themost signiﬁcant the previous report of acute toxicity. After quality data assessment 552,597markers
were evaluated. From these, seven and eighteen loci showed p values lower that 1×10−5 for the development of acute and late
radio-induced toxicity, respectively.
Conclusions. We have identiﬁed new genetic loci associates with overall radiotherapy toxicity by using a genome wide association
design. These results must be replicated in an independent cohort to be validated.
http://dx.doi.org/10.1016/j.rpor.2013.03.819
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Objectives. The aim of this study is to assess the biochemical non-evidence of disease survival (bNEDs), disease free survival (DFS),
and overall survival (OS) rates, as well as, to identify some of prognostic factors associated with this outcomes in intermediate
risk prostate cancer patients in the context of a multi-institutional Spanish database (RECAP).
Materials/methods. Patient selectionwas accordingNCCN criteria and all of patientswere treatedwith external beam radiotherapy.
Related variables included age, PSA, Gleason score, cT stage, number of positive cores, Androgen Deprivation Therapy (ADT) and
external radiation dose.
Results. A total of 1878 patients were included. Median age was 71 years (range: 47–86). Mean initial PSA was 10.24ng/ml (range
6–20ng/ml). Clinical stage T1 and T2 was 35% and 65%, respectively. 25% had Gleason score 6 and 75% Gleason score 7. Median
radiation dose to prostate was 74Gy (range: 66–76Gy) and 76% of patients received ADT. With a median follow-up of 61 months,
the 5-year and 10-year bNEDs was 92% and 78% respectively, 96 and 89% DFS and 98% and 95% for OS. There were not grade 3 GI
or GU acute and late toxicity. Multivariate analysis to determine independent prognostic factors for biochemical control will be
presented after the last follow-up.
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Conclusions. This is a large multi-institutional retrospective Spanish data base (RECAP) study of intermediate risk prostate cancer
patients treatedwith external beam radiation therapy. Outcomes (biochemical control and survival) are high,with a low incidence
of acute and late toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.820
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Background. IMRT allows higher doses being delivered to the prostate gland sparing organs at risk and as a result, it is increasingly
used to treat localized prostate cancer (LPC). There is, however, concern about increased risks of late toxicity.
Purpose. To report acute and late gastrointestinal (GI) and genitourinary (GU) toxicity after 79.6Gy delivered with IMRT in LPC,
and to evaluate predictors of treatment-related toxicity.
Methods and materials. Consecutive 671 patients with LPC cT1-3 stages were treated with dose-escalation radiotherapy from 1999
to 2011. Inclusion criteria included: no previous pelvic radiotherapy, radiation dose>72Gy and minimum follow-up>12 months.
437 patients were treated with three-dimensional conformal radiotherapy (3DCRT) and 234 with IMRT/IGRT using intra-prostate
gold ﬁducial markers. Median dose was 78.6Gy and 79.6Gy, respectively. Acute and late toxicities were graded according to the
Common Terminology Criteria for Adverse Events 4.0. Analyses were carried out using SPSS 17.0.
Results. Median follow-up for the entire cohort was 58 months (range, 12–170 months). Compared to 3DCRT, overall toxicity was
lower in the IMRT group. Grade 2 or higher complications were very low: 4.8% acute GI, 14.5% acute GU, 3% late GI and 3% late
GU. Late rectal bleeding in the 3DCRT and IMRT was 7.1% and 2.6%, respectively (p=0.015). Multivariate analysis showed that
intraprostatic ﬁducial-guided IMRT (odds ratio = 0.628, p=0.018) and presence of rectal symptoms during RT (odds ratio = 2.314,
p=0.000) correlated with GI late toxicity.
Conclusions. High-dose IMRT with intraprostatic ﬁducial markers has a signiﬁcantly lower rate of GI and GU complications
compared to 3DCRT. The presence of acute rectal toxicity can predict a higher risk of late GI toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.821
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Purpose. Few studies have evaluated the relation between dose–volume histograms (DVH) and toxicity in prostate cancer and
even fewer studies have studied the association between DVH and health-related quality of life (HRQL). The aim of this study
was to assess the correlation between DVH in organs at risk (OAR) outcomes as measured with speciﬁc HRQL questionnaire
Methodology. Between January 2003 and November 2005 a total of 190 patients with clinically localized prostate cancer were
recruited in Catalan Institute of Oncology to participate in a multicentric study of HRQL following radical prostatectomy, external
beam radiotherapy and prostate brachytherapy treatment for clinically localized prostate cancer. Inclusion criteria were stages
T1 or T2 and low risk prostate cancer. HRQL was evaluated by two generic questionnaire (SF-36, FACT-G) and several speciﬁc
questionnaire (FACT-P, EPIC, IPSS and IEEF). DVH for OARs (penile bulb, rectum and bladder) were created for 119 of the 190
patients to assess the correlation between DVH and HRQL using Functional Data Analysis.
Results. The distribution dose–volume (DDV) in the rectum was higher in patients with faecal blood and loose stools compared
to patients without such toxicity when the DDV was between 0–40Gy and 20–70Gy respectively. At all points on the bladder
DDV curve, the DDV was higher in patients with urinary incontinence than in patients without toxicity. We found no relation
between the presence of Urinary obstructive side effects and the DDV. Although many patients had Sexual function impairment,
we found no association between this side effect and penile bulb DDV.
Conclusion. The results of his study suggest that the entire range of the dose volume curvemust be considered to assess correlation
between the histogram and quality of life, because correlations could appear only in a limited part of the DVH. Functional Data
Analysis was a valuable tool to properly analyze the DVH data. These results could help radiation-oncologists to select the best
treatment from among the various treatment strategies in order to achieve the best quality of life outcomes.
http://dx.doi.org/10.1016/j.rpor.2013.03.822
